Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPY1R | P25929 | 1/20 | 0.36 |
| ▸ | NPY2R | P49146 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3938174 | 0.86 | CA1 (0.35) | CA12CA1CA2CA9CA7 | |
| SCHEMBL3725124 | 0.86 | KDM4E (0.34) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL2793251 | 0.77 | GAA (0.58) | GAACA12CA1CA2CA9 | |
| SCHEMBL3929329 | 0.74 | HTT (0.37) | GAACA12CA1CA2CA9 | |
| SCHEMBL25304499 | 0.73 | SLC6A3 (0.49) | GAACA1CA2CA9SMN1; SMN2 | |
| SCHEMBL7415528 | 0.73 | CA12 (0.55) | GAACA12CA1CA2CA9 | |
| SCHEMBL2424582 | 0.73 | LMNA (0.38) | CA1CA2SMN1; SMN2LMNAHPGD | |
| SCHEMBL3661787 | 0.72 | HTT (0.46) | GAACA12CA1CA2CA9 | |
| SCHEMBL30463099 | 0.71 | CA12 (0.53) | GAACA12CA1CA2CA9 | |
| SCHEMBL2726967 | 0.71 | CA12 (0.53) | GAACA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101553493-A | Novel tricyclic spiropiperidine compounds, their synthesis and their use as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2009-10-07 | — | — | CN | claimed |
| CN-101553493-B | Tricyclic spiropiperidine compounds, their synthesis and their use as modulators of chemokine receptor activity | ASTRAZENECA AB | 2012-07-04 | — | — | CN | disclosed |
| CN-101553493-A | Novel tricyclic spiropiperidine compounds, their synthesis and their use as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2009-10-07 | — | — | CN | disclosed |
| US-20090176815-A1 | Novel Tricyclic Spiropiperidine Compounds, Their Synthesis and Their Uses as Modulators of Chemokine Receptor Activity | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | disclosed |
| US-20090176815-A1 | Novel Tricyclic Spiropiperidine Compounds, Their Synthesis and Their Uses as Modulators of Chemokine Receptor Activity | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | disclosed |
| US-20090176815-A1 | Novel Tricyclic Spiropiperidine Compounds, Their Synthesis and Their Uses as Modulators of Chemokine Receptor Activity | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | disclosed |
| EP-2069355-A1 | NOVEL TRICYCLIC SPIROPIPERIDINE COMPOUNDS, THEIR SYNTHESIS AND THEIR USES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2009-06-17 | — | — | EP | disclosed |
| WO-2009011654-A1 | PROCESS FOR THE PREPARATION OF CYCLIC SPIROPIPERIDINES | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009011654-A1 | PROCESS FOR THE PREPARATION OF CYCLIC SPIROPIPERIDINES | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009011655-A1 | SPLROPIPERIDINE COMPOUNDS, A PROCESS OF THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THE TREATMENT OF AIRWAY DISEASES, INFLAMMATORY DISEASES, COPD OR ASTHMA | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009011655-A1 | SPLROPIPERIDINE COMPOUNDS, A PROCESS OF THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THE TREATMENT OF AIRWAY DISEASES, INFLAMMATORY DISEASES, COPD OR ASTHMA | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | WO | disclosed |
| US-20080167332-A1 | Novel Compounds 243 | ASTRAZENECA AB (SE) | 2008-07-10 | — | — | US | disclosed |
| US-20080167332-A1 | Novel Compounds 243 | ASTRAZENECA AB (SE) | 2008-07-10 | — | — | US | disclosed |
| US-20080167332-A1 | Novel Compounds 243 | ASTRAZENECA AB (SE) | 2008-07-10 | — | — | US | disclosed |
| WO-2008010765-A1 | NOVEL TRICYCLIC SPIROPIPERIDINE COMPOUNDS, THEIR SYNTHESIS AND THEIR USES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008010765-A1 | NOVEL TRICYCLIC SPIROPIPERIDINE COMPOUNDS, THEIR SYNTHESIS AND THEIR USES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167332-A1 | Novel Compounds 243 | UGT1A10, ABCG2, VKORC1L1 | GAA 1758/4885CA12 3549/4885CA1 4463/4885 |
| US-20090176815-A1 | Novel Tricyclic Spiropiperidine Compounds, Their Synthesis and Their Uses as Modulators of Chemokine Receptor Activity | ACKR3, CCR2, CCR5 | GAA 4858/4885CA12 4542/4885CA1 4346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.